Repligen Completes $1.5 Billion BioLife Solutions Acquisition
The bioprocessing company closed the mixed cash-and-stock deal that was expected to be accretive to adjusted earnings by at least 25 cents in year two.
Repligen Corporation (RGEN) completed its acquisition of BioLife Solutions, Inc. (BLFS), converting the cell-therapy tools company into a wholly owned subsidiary and taking BioLife off Nasdaq.
The life sciences company, which had agreed in July to buy BioLife for a total enterprise value of approximately $1.5 billion, closed the merger on October 6, 2026. Each outstanding share of BioLife common stock converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, a mix the companies had described as 36% cash and 64% stock, with cash in lieu of any fractional Repligen shares.
Repligen said the deal was expected to be accretive to top-line growth, adjusted margins, and adjusted earnings per share by at least 5 cents in year one and at least 25 cents in year two. The cash component was funded from cash on hand, and the company said its balance sheet was expected to remain healthy with greater than $300 million of pro forma cash and cash equivalents.
President and Chief Executive Officer Olivier Loeillot said at the announcement that BioLife’s portfolio would expand Repligen’s presence in the rapidly growing cell therapy market and add a high-margin consumables business with recurring revenue. Repligen’s employee FAQ said BioLife’s products are specified in 18 commercially approved cell therapies and the majority of U.S. commercially sponsored cell-based therapy trials, with approximately 98% of revenue in consumables.
Immediately before the First Merger Effective Time, BioLife options, time-based and performance-based restricted stock units, and unvested restricted stock accelerated, vested in full, and were settled in BioLife shares, which then converted into the same cash-and-stock merger consideration.
BioLife, based in Bothell, Washington, with about 160 employees, had reported preliminary second-quarter revenue of $28.5 million, up 21% from $23.4 million a year earlier. Repligen had reported second-quarter revenue of $204 million, up 12% as reported and 13% organically, and raised full-year 2026 organic revenue growth guidance to 10.5%–13.5% and adjusted EPS to $2.03–$2.09.
On October 5, BioLife asked Nasdaq to halt trading after the aftermarket session and, subject to confirmation of closing, to suspend trading and file a Form 25 to delist the stock. On October 6, BioLife notified Nasdaq that the mergers had closed and said it intended to file a Form 15 to terminate registration of the common stock under Section 12(g) and suspend its Exchange Act reporting obligations.